Literature DB >> 34206078

MyD88 Is Not Required for Muscle Injury-Induced Endochondral Heterotopic Ossification in a Mouse Model of Fibrodysplasia Ossificans Progressiva.

Huili Lyu1,2, Cody M Elkins1, Jessica L Pierce1, C Henrique Serezani3, Daniel S Perrien1.   

Abstract

Excess inflammation and canonical BMP receptor (BMPR) signaling are coinciding hallmarks of the early stages of injury-induced endochondral heterotopic ossification (EHO), especially in the rare genetic disease fibrodysplasia ossificans progressiva (FOP). Multiple inflammatory signaling pathways can synergistically enhance BMP-induced Smad1/5/8 activity in multiple cell types, suggesting the importance of pathway crosstalk in EHO and FOP. Toll-like receptors (TLRs) and IL-1 receptors mediate many of the earliest injury-induced inflammatory signals largely via MyD88-dependent pathways. Thus, the hypothesis that MyD88-dependent signaling is required for EHO was tested in vitro and in vivo using global or Pdgfrα-conditional deletion of MyD88 in FOP mice. As expected, IL-1β or LPS synergistically increased Activin A (ActA)-induced phosphorylation of Smad 1/5 in fibroadipoprogenitors (FAPs) expressing Alk2R206H. However, conditional deletion of MyD88 in Pdgfrα-positive cells of FOP mice did not significantly alter the amount of muscle injury-induced EHO. Even more surprisingly, injury-induced EHO was not significantly affected by global deletion of MyD88. These studies demonstrate that MyD88-dependent signaling is dispensable for injury-induced EHO in FOP mice.

Entities:  

Keywords:  Acvr1; FAP; IL-1β; MyD88; chondrogenesis; fibroadipoprogenitor; muscle injury and repair; osteogenesis

Year:  2021        PMID: 34206078     DOI: 10.3390/biomedicines9060630

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  4 in total

Review 1.  Pathophysiology and Emerging Molecular Therapeutic Targets in Heterotopic Ossification.

Authors:  Favour Felix-Ilemhenbhio; George A E Pickering; Endre Kiss-Toth; Jeremy Mark Wilkinson
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

2.  Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery.

Authors:  Yeon-Suk Yang; Jung-Min Kim; Jun Xie; Sachin Chaugule; Chujiao Lin; Hong Ma; Edward Hsiao; Jaehyoung Hong; Hyonho Chun; Eileen M Shore; Frederick S Kaplan; Guangping Gao; Jae-Hyuck Shim
Journal:  Nat Commun       Date:  2022-10-19       Impact factor: 17.694

Review 3.  Contemporary perspectives on heterotopic ossification.

Authors:  Charles D Hwang; Chase A Pagani; Johanna H Nunez; Masnsen Cherief; Qizhi Qin; Mario Gomez-Salazar; Balram Kadaikal; Heeseog Kang; Ashish R Chowdary; Nicole Patel; Aaron W James; Benjamin Levi
Journal:  JCI Insight       Date:  2022-07-22

4.  Editorial of Special Issue "Fibrodysplasia Ossificans Progressiva: Studies on Disease Mechanism towards Novel Therapeutic Approaches".

Authors:  Roberto Ravazzolo
Journal:  Biomedicines       Date:  2022-01-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.